a cytogenetically normal (CN) phenotype, which would make additional prognostic factors particularly useful in this group [5, 6] .
Introduction
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues, with maturation arrest of cells in the bone marrow and impaired production of normal blood cells [1, 2] .
Treatment strategies of patients with AML are based on various prognostic factors, including age and performance status of the patient, as well as cytogenetic and molecular characteristics of the leukemic clone [3] .
To date, cytogenetic abnormalities have provided the most prognostic information [4] . However, 40%-49% of adult AML patients have performed using Becton Dickinson, FACSCalibur flow cytometer equipped with Cell Quest software (USA) [14] [15] [16] .
Immunophenotyping analysis
The 
Results
Our group of AML patients consisted of 26 males (52%) and 24 females (48%). Their ages ranged from 14 to 82 years, with a mean of 41.2 years; only three patients were above 60 years of age. Demographic, clinical, and laboratory data are presented in table I. Our diagnosis was based on morphology, BM aspiration, and immunophenotyping. No other molecular markers were investigated in our study because of financial constraints.
Positive CD25 expression was found in 12 cases (24%) in our studied group (Fig. 1) . Karyotyping was successfully done in 11 cases The response of our patients was highly variable: 32 patients (64%) achieved CR from the first induction treatment and were doing well until the end of the study; three patients (6%) had a relapse after achieving CR; and 15 patients died (seven were nonresponders and died of acute respiratory distress syndrome (ARDS) and intracranial hemorrhage; three died during their first induction treatment from septicemia; and five died in the consolidation phase from sepsis or intracranial hemorrhage). None of our patients had BM transplantation.
On comparing CD25-positive and -negative patients in terms of the demographic data, clinical findings, CBC results, and karyotyping, no statistically significant difference was found (Tab. I, Fig. 2 ).
We tried to study the relation between CD25 expression and outcome and found that the CD25-positive group had significantly higher relapse and death rates (P = 0.011 and P = 0.027, respectively), apart from significantly lower remission rates (P < 0.001).
On combining the karyotype results with those of CD25 expression, CD25-positive AML patients with normal karyotype had a significantly lower remission rate and significantly higher relapse and death rates when compared with CD25-negative patients with normal karyotype (P = 0.025). Thus, CD25 added a significant prognostic value to the patients with intermediate cytogenetic risk (normal karyotype) (Tab. II). Overall survival (OS) and leukemia-free survival (LFS) were studied in relation to age and CD25 expression. CD25-positive patients were associated with significantly worse OS (P = 0.008) (Fig. 3 A) , shorter LFS (P < 0.001) (Fig. 3 B) , and lower mean survival (7.9 months) in comparison with CD25-negative patients (14.4 months).
No significant differences between the age groups below and above 60 years in terms of OS(P = 0.084) and LFS (P = 0.130) were found (Fig. 4) .
We used the age, sex, white blood cell (WBC) count, hemoglobin concentration, platelet count, karyotype, percentage of blasts in the peripheral blood and BM, CD34 expression on the blast cells, and CD25 expression on the blast cells in our univariate analysis and then in the multivariate analysis against the outcome. In the univariate analysis, CD25 positivity was a strong predictor for bad outcome and worse prognosis (P < 0.001). In the multivariate analysis, CD25 positivity was the most powerful independent predictor for bad prognosis (P = 0.002). and chemotherapy-resistant leukemia stem cells (LSCs) [23] , which requires newer therapeutic approaches targeting IL-2Ra to improve the prognosis of this type of AML.
Discussion
Therefore, we aimed to evaluate CD25 expression in 50 newly diagnosed adult Egyptian patients with de novo AML, who were treated by the standard ''3+7'' protocol, correlate its expression with the biological characteristics of the disease and the clinical response, as well as assess its prognostic value, especially in the largest cytogenetic subclass of AML (those patients with a normal karyotype and patients with prognostically noninformative cytogenetic aberrations). We found that 24% of our patients had CD25-positive blasts at diagnosis. [24] reported that 13% (87/657) of their AML patients had CD25-positive AML, while Fujiwara et al [25] demonstrated
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Recommendations
Further studies need to be performed on CD25-positive AML patients on a wider scale to study other factors that might influence the results of chemotherapy treatment as well as to investigate other treatment strategies for CD25-positive AML.
Since the detection of CD25 is relatively straightforward and fast, we recommend that immunophenotypic detection of CD25 should be considered as a part of the routine workup of AML patients with normal karyotype, since it helps dissecting this heterogeneous cytogenetic category into prognostically different subgroups.
